Inflammatory Biomarkers in Saliva at Depression

Depression Clinical Trial

Official title:

Salivary Biomarkers of Gingival Inflammation Are Associated With Depression

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06427902
• Other study ID #: Depression
• Status: Completed
• Start date: December 10, 2018
• Est. completion date: September 16, 2019

Study information

• Verified date: May 2024
• Source: Medipol University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to evaluate the inflammatory saliva biomarkers in depression and gingivitis.

The main question will be ; Will there be an increase at salivary biomarkers with depression patients and is it associated with gingivitis?

Description:

Background: The neuroimmune regulation disorder in depression patients causes the progression of inflammatory periodontal disease. The present study was to evaluate the periodontal health status and the levels of Triggering receptor expressed on myeloid cells 1 (TREM-1), peptidoglycan recognition protein 1 (PGLYRP1) and interleukin-1 beta (IL-1β) in individuals diagnosed with depression and to compare these findings with those of systemically healthy individuals.

Methods: Forty-two depression patients were classified in two groups: depression with gingivitis (DG) and depression with periodontally healthy (DPH) patients. Additionally, 23 systemically and periodontally healthy (SPH) individuals were enrolled to the study. Periodontal parameters were recorded. Saliva samples were collected and salivary levels of TREM-1, PGLYRP1, IL-1β were measured using Enzyme-linked Immunosorbent Assay (ELISA) kits.

depression regardless of periodontal status.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: September 16, 2019
• Est. primary completion date: June 14, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 53 Years

Eligibility

Inclusion Criteria:

• Patients who were moderate in severity according to the test result, who had not started drug therapy yet and who had not received antidepressant medication in the last 12 months

Exclusion Criteria: Patients with

• psychotic disorders

• autism spectrum disorders

• other anxiety disorders

• bipolar disorder

• mental any organic mental disorder and

• smokers, substance users

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Gingivitis
• Inflammation
• Inflammatory Response

Intervention

Other:
• Periodontal clinical measurements, Saliva sampling
Clinical periodontal indices; Probing depth, Clinical attachment level, bleeding on probing, gingival index, and plaque

Locations

Country	Name	City	State
Turkey	Duygu Ilhan	Istanbul	Select State

Sponsors (1)

Lead Sponsor	Collaborator
Medipol University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SalivaryTREM-1	Both, soluble and membrane-bound TREM-1, are detected by the TREM-1 ELISA.	06-09 2019
Primary	Salivary PGLYRP1	Both, soluble and membrane-bound PGLYRP1 are detected by the PGLYRP1 ELISA.	06-09 2019
Primary	Salivary IL-1ß	Both, soluble and membrane-bound IL-1ß detected by the IL-1ß ELISA.	06-09 2019